艾尔建新闻发布|艾伯维新闻中心狗万平台活动

<！[CDATA [AbbVie公司。完成对Allergan plc的收购

2020年5月8日星期五美国东部时间16:20:00

都柏林，2020年5月8日/PRNewswire/ - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN all OR PART, IN爱力根股份有限公司(NYSE:AGN)(“< >强爱力根< / >强“)宣布AbbVie已经完成了收购爱力根依照计划安排在第9部分的第一章2014年爱尔兰公司法案(“< >强计划< / >强“),今天早些时候生效,2020年5月8日。< / p >

<！爱力根基金会的COVID-19应对捐款翻倍至400万美元

星期四，07年5月20日09:00:00 EST

<陆位置值= " / ie . .都柏林" idsrc="//www.worldcupnut.com/stories/xmltag.org">都柏林， May 7, 2020 /PRNewswire/—— (纽约证交所:AGN)今天宣布，爱力根基金会(Allergan Foundation)已快速获得另一笔200万美元的慈善赠款，用于社区组织应对COVID-19大流行。到目前为止，爱力根基金会(Allergan Foundation)对COVID-19的总捐赠增加了一倍，总额达到$ 400万。这些捐款将专门用于在纽约抗击疫情的社区第一线工作的57个组织。>New York， New Jersey， California，德州，俄亥俄，佛罗里达和国际。

<！[有关法院制裁听证会结果的公告]]>

2020年5月6日星期三06:55:00

<陆位置值= " / ie . .dublin" idsrc="//www.worldcupnut.com/stories/xmltag.org">DUBLIN, May 6, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Allergan by AbbVie Inc. ("AbbVie") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").

<！[CDATA[关于Allergan Notes自愿退市的公告]]>

美国东部时间2020年4月28日

<陆位置值= " / ie . .dublin" idsrc="//www.worldcupnut.com/stories/xmltag.org">DUBLIN, April 28, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") announced today that it has notified the New York Stock Exchange ("NYSE") of its intention to voluntarily withdraw from listing on the NYSE and from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") any and all outstanding notes and related guarantees of the following series issued by Allergan Funding SCS, a subsidiary of Allergan: (i) Floating Rate Notes due 2020 (NYSE: AGN20A), (ii) 0.500% Senior Notes due 2021 (NYSE: AGN21), (iii) 1.500% Senior Notes due 2023 (NYSE: AGN23A), (iv) 1.250% Senior Notes due 2024 (NYSE: AGN24A), (v) 2.625% Senior Notes due 2028 (NYSE: AGN28) and (vi) 2.125% Senior Notes due 2029 (NYSE: AGN29) (clauses (i)-(vi) collectively, the "Allergan Funding SCS Notes") in each case, following the consummation of the previously announced proposed acquisition (the "Transaction") of Allergan by AbbVie Inc. ("AbbVie") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014. The proposed delisting of the Allergan Funding SCS Notes and related guarantees is contingent upon the closing of the Transaction, which is subject to, among other conditions, the receipt of necessary regulatory approvals. To effect the delisting, Allergan expects Allergan Funding SCS and each guarantor of the Allergan Funding SCS Notes to file a Form 25 in respect of the Allergan Funding SCS Notes with the Securities and Exchange Commission. Allergan reserves the right to delay the filing of the Form 25 or to withdraw such filing for any reason prior to its effectiveness, including, without limitation, in the event that the Transaction is delayed or is not completed for any reason.

<！[CDATA[中国为Allergan's XEN®难治性青光眼手术管理注册提供绿灯]]>

星期四，02 Apr 2020 07:30:00 EST

—XEN^® Becomes the First Medical Product by Using Real World Evidence in China - ， Allergan plc(纽交所:2020年3月26日，国家药品监督管理局(NMPA)批准Allergan的XEN^® Gel Stent在注册，用于难治性青光眼患者的手术治疗。XEN^®是首个通过Real World Evidence途径在China获批的产品。

<！[CDATA[Allergan earned ENERGY STAR®the Year - Sustained Excellence Award for the Year]]>

Tue, 31 Mar 2020 10:05:00 EST

dublin ， 3月31,2020 / prnewswire / - Allergan PLC （纽约证券交易所：AGN）今天宣布它已收到了2020年的年度持续卓越奖的能源之星^{®合伙人，连续第七次标志着一年它赢得了能源之星^{®的最高荣誉。 U.S。环境保护署奖励确认其在能源管理和效率方面的持续领导力。}}

<！[CDATA [Allergan基金会在Covid-19响应前线上的社区组织捐赠了2.0百万美元]]>

星期一，30 Mar 2020 09:40:00 EST

<陆位置值= " / ie . .都柏林" idsrc="//www.worldcupnut.com/stories/xmltag.org">都柏林， March 30, 2020 /PRNewswire/——爱力根(Allergan)今日宣布，爱力根基金会(Allergan Foundation)将于2020年向爱力根提供约1300万美元的慈善赠款，作为其承诺的一部分，为爱力根员工生活和工作的社区提供持久和积极的影响。2020年的捐款支持致力于应对COVID-19大流行的项目，以及支持精神卫生、Eye Care和Breast Health的举措。2020年的资助将使Allergan基金会在其22年的历史上的总捐赠约为 1.08亿美元，其中 5700万美元。

<！[CDATA[Allergan宣布2020年第二季度每股普通股现金股利为0.74美元]

星期三，18 Mar 2020 07:30:00 EST

<陆位置值= " / ie . .2020年3月18日，爱力根公司(NYSE: AGN)今日宣布，其董事会宣布2020年第二季度每股现金股利为$0.74。该股息将在艾伯维收购艾尔建(Allergan)的截止日期支付，该收购仍需获得监管部门批准和惯例交割条件。如果尚未完成交割，股息将在 2020年6月15日支付。爱力根2020年第二季度的股息将于2020年4月16日营业结束时支付给股东。

<！[CDATA[根据爱尔兰收购规则发布的公告:相关证券发行- 2020年3月10日]]>

Tue, 10 Mar 2020 07:30:00 EST

<陆位置值= " / ie . .dublin" idsrc="//www.worldcupnut.com/stories/xmltag.org">DUBLIN, March 10, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on March 6, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 329,172,167 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

<！[CDATA[Allergan received FDA Approval for DURYSTA™(bimatoprost植入物)the First and Only Intracameral Biodegradable缓释植入物用于降低开角型青光眼或眼高压患者的眼压

周四，05 Mar 2020 09:44:00 EST

dublin ， 3月5,2020 / prnewswire / - Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for intracameral administration. With this approval, DURYSTA™ becomes the first intracameral, biodegradable sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

<！[CDATA[根据爱尔兰收购规则发布的公告:相关证券发行- 2020年3月3日]]>

Tue, 03 Mar 2020 16:15:00 EST

<陆位置值= " / ie . .dublin" idsrc="//www.worldcupnut.com/stories/xmltag.org">DUBLIN, March 3, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on March 2, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 329,125,399 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

<！[CDATA[Allergan在美国青光眼协会年度会议上公布调查性比马前列素缓释的新数据]

Tue, 25 Feb 2020 07:30:00 EST

dublin ， 2月。25、2020 /PRNewswire/——在美国青光眼协会(American Glaucoma Society)召开的年会上，全球领先的制药公司AGN (AGN)将公布Bimatoprost缓释(SR)研究的新数据。来自3期ARTEMIS研究的数据将在口头会议期间提交，并将提供视野(VF)结果以及Bimatoprost SR对开角型青光眼(OAG)患者疾病进展的影响。Bimatoprost SR的新药申请(NDA)目前正在审查中，其价值U.S.>，如果获得批准，有望成为第一个也是唯一一个生物可降解的房内植入物，通过缓释给药系统降低开角型青光眼或高眼压患者的眼压。

<！[CDATA[根据爱尔兰收购规则发布的公告:发行的相关证券- 2020年2月14日]]>

星期五，2月14日2月16:15:00 Est

dublin ， 2月。14, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on February 13, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 328,998,524 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

<！[根据《爱尔兰收购规则》第8.1(a)条发布的公告:要约人、受要约人或与其一致行事的各方为自己或任意客户进行的交易]]>

2020年2月14日星期五07:00:00 EST

dublin ， 2月。14, 2020 /PRNewswire/ -- 1. KEY INFORMATION 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

<！[CDATA [allergan报告第四季度和全年2019财务结果]]>

星期一，10 Feb 2020 07:00 EST

< span > <陆位置值= " / ie . .都柏林都柏林”idsrc = " xmltag.org " > < /位置> < / span >, <时间> 2月。2020 < /时间> < span > /价值/——< org value = " NYSE: AGN " idsrc = " xmltag.org " >爱力根公司< / org > (NYSE: AGN)今天公布了2019年全年和2019年第四季度财务结果包括全年GAAP净营收的钱< > < / >资金161亿美元,比2018年增长了1.9%。2019年第四季度GAAP净收入为<货币> 43.5亿美元<货币>，较上年同期增长6.6%

<！[CDATA[BOTOX®Cosmetic (onabotulinumtoxinA) Launches Be The Difference Philanthropic Program]]>

星期一，03 Feb 2020 07:30:00 EST

dublin ， 2月。3、2020年 /PRNewswire/ - (NYSE: AGN)今日宣布其Be The Difference慈善计划，支持可能受益于BOTOX^®(onabotulinumtoxinA)治疗小儿上肢麻痹的儿童及其家庭。BOTOX^®被批准用于治疗2至17岁上肢痉挛儿童肌肉僵硬增加。在美国，BOTOX^®化妆品被批准用于3种美容适应症，BOTOX^®被批准用于11种治疗适应症。艾尔建的忠诚奖励计划将帮助艾尔建向基金会捐款，总额为50万美元，帮助全国各地的儿童。

<！[CDATA[Allergan to Report Fourth Quarter and Full Year 2019 Financial Results]

星期五，1月31日2020年07日07:30:00

<陆位置值= " / ie . .都柏林都柏林”idsrc = " xmltag.org " > < /位置>,<时间> 1月。31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release fourth quarter and full year 2019 financial results on Monday, February 10, 2020, prior to the open of U.S. financial markets. For additional materials related to Allergan's fourth quarter and full year 2019 financial results, please visit Allergan's Investor Relations website at https://www.allergan.com/investors.

<！[CDATA [IRISH收购规则下的公告：发行相关证券 - 2012年1月30日]]>

2020年1月30日星期四美国东部时间16:15:00

<陆位置值= " / ie . .都柏林都柏林”idsrc = " xmltag.org " > < /位置>,<时间> 1月。30, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on January 28, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 328,763,705 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

<！[CDATA[Allergan宣布2020年第一季度普通股现金股利为0.74美元]

2020年1月24日星期五07:00:00美国东部时间

<陆位置值= " / ie . .都柏林都柏林”idsrc = " xmltag.org " > < /位置>,<时间> 1月。爱力根公司(NYSE: AGN)今日宣布，其董事会宣布2020年第一季度每股现金分红为$0.74。股息将于2020年3月13日于2020年2月14日 >收盘时向记录股东支付。

<！[CDATA[SkinMedica®推出全新即时明亮眼霜，即刻见效]]>

2020年1月17日星期五07:30:00 EST

<陆位置值= " / ie . .都柏林都柏林”idsrc = " xmltag.org " > < /位置>,<时间> 1月。2020年，爱力根(Allergan)今日宣布推出SkinMedica^® Instant Bright Eye Cream，这是一款提神的眼部护理产品，补水、亮白并明显紧致眼部娇嫩肌肤。该产品旨在立即改善眼睛的外观，并持续减少随时间推移的衰老和疲劳迹象，包括黑眼圈，细纹和上眼睑的皱纹。sup>®为最全面的护肤方案，还推出了即时亮眼眼膜，一套水凝胶眼罩，减少浮肿的出现，并为眼部提供补水。